Literature DB >> 23099230

Adherence to antiepilepsy drug therapy.

Edward Faught1.   

Abstract

Adherence to antiepilepsy drug (AED) therapy is critical for effective disease management, yet adherence and persistence rates are low due to several barriers. The definitions of adherence (80% rate of total pills taken, medication possession ratio, and days covered by prescriptions filled) and methods of measurement (patient self-reports, serum drug levels, pill counts, electronic bottle tops, and reviews of pharmacy records) are not without limitations, and their applicability to epilepsy is not clear. The use of simple adherence scales during office visits can provide an overall impression of a patient's adherence and can serve as a basis for practitioner-patient dialog. Efforts to improve adherence should focus on provider and healthcare system determinants versus those focused only on the patient. These interventions include non-judgmental communication, patient education, simplification of the dosage regimen with once-daily therapies, and the use of patient reminders.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23099230     DOI: 10.1016/j.yebeh.2012.08.027

Source DB:  PubMed          Journal:  Epilepsy Behav        ISSN: 1525-5050            Impact factor:   2.937


  20 in total

Review 1.  Update on Medication Use Quality and Safety in Older Adults, 2017.

Authors:  Shelly L Gray; Zachary A Marcum; Kenneth E Schmader; Joseph T Hanlon
Journal:  J Am Geriatr Soc       Date:  2018-11-13       Impact factor: 5.562

2.  Epilepsy, antiepileptic drugs, and serious transport accidents: A nationwide cohort study.

Authors:  Heléne E K Sundelin; Zheng Chang; Henrik Larsson; Paul Lichtenstein; Catarina Almqvist; Torbjörn Tomson; Jonas F Ludvigsson
Journal:  Neurology       Date:  2018-02-28       Impact factor: 9.910

3.  Medication adherence in women with epilepsy who are planning pregnancy.

Authors:  Lia de Leon Ernst; Cynthia L Harden; Page B Pennell; Nichelle Llewellyn; Connie Lau; Sarah Barnard; Eyal Bartfeld; Jacqueline A French
Journal:  Epilepsia       Date:  2016-10-25       Impact factor: 5.864

Review 4.  A review of the efficacy and safety of eslicarbazepine acetate in the management of partial-onset seizures.

Authors:  Rodrigo Rocamora
Journal:  Ther Adv Neurol Disord       Date:  2015-07       Impact factor: 6.570

5.  Adherence to antiepileptic drugs among diverse older Americans on Part D Medicare.

Authors:  Kendra Piper; Joshua Richman; Edward Faught; Roy Martin; Ellen Funkhouser; Jerzy P Szaflarski; Chen Dai; Lucia Juarez; Maria Pisu
Journal:  Epilepsy Behav       Date:  2016-12-27       Impact factor: 2.937

6.  Adherence to Antiseizure vs Other Medications Among US Medicare Beneficiaries With and Without Epilepsy.

Authors:  Samuel Waller Terman; Wesley T Kerr; Carole E Aubert; Chloe E Hill; Zachary A Marcum; James F Burke
Journal:  Neurology       Date:  2021-12-10       Impact factor: 9.910

7.  Antiseizure medication adherence trajectories in Medicare beneficiaries with newly treated epilepsy.

Authors:  Samuel W Terman; Wesley T Kerr; Zachary A Marcum; Lu Wang; James F Burke
Journal:  Epilepsia       Date:  2021-08-31       Impact factor: 5.864

8.  Frequencies of UGT1A4*2 (P24T) and *3 (L48V) and their effects on serum concentrations of lamotrigine.

Authors:  Arne Reimers; Wenche Sjursen; Grethe Helde; Eylert Brodtkorb
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2014-12-10       Impact factor: 2.441

9.  A novel open-source drug-delivery system that allows for first-of-kind simulation of nonadherence to pharmacological interventions in animal disease models.

Authors:  Kyle E Thomson; H Steve White
Journal:  J Neurosci Methods       Date:  2014-09-26       Impact factor: 2.390

10.  Factors associated with 30-day readmission for patients hospitalized for seizures.

Authors:  Samuel W Terman; Elan L Guterman; Chloe E Hill; John P Betjemann; James F Burke
Journal:  Neurol Clin Pract       Date:  2020-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.